|
**
Denotes trial that will have an ACC News Conference
SUNDAY,
MARCH 12
Late-Breaking
Trial in Interventional Cardiology (#72), Arena
Co-Chairs: Robert M. Califf and Richard E. Kuntz
8:45
a.m.
**One-Year Follow-Up of Patients
With Refractory Angina Randomized to Percutaneous Transmyocardial
Revascularization vs. Medical Therapy
Emerson C. Perin, of Houston
9:00
a.m.
**Phase II, Multicenter, Double-Blind,
Placebo-Controlled, Dose-Finding Study for Safety, Pharmacokinetics,
and Efficacy of Recombinant Fibroblast Growth Factor
(rFGF-2) in Subjects With Coronary Artery Disease (CAD)
Michael Simons, of Boston
9:15
a.m.
90SR Treatment
of Angiographic Restenosis Trial(START)
Jeffrey J. Popma, of Boston
9:30
a.m.
A Randomized, Double-Blind,
Dose-Escalation Trial Assessing Safety and Efficacy
of FFR- FVIIa in PTCA (ASIS)
Michael Lincoff, of Cleveland
9:45
a.m.
Intracoronary Stenting
or Angioplasty for Restenosis Reduction in Small Vessels:
ISAR-Small Vessels
Adnan Kastrati, of Munich, Germany
MONDAY, MARCH 13
Late-Breaking
Clinical Trials I (#405), Ballroom C
Co-chairs: John S. Douglas, Jr., and Judith S. Hochman
9:15
a.m.
Beta-Blocker Length of Stay Study
(BLOSS)
Stuart J. Connolly, of Hamilton, Ontario, Canada
9:30
a.m.
**Estrogen Replacement and Atherosclerosis
(ERA)
David M. Herrington, of Winston-Salem, N.C.
9:45
a.m.
Final Results of the BEstent
in SMall ARTeries (BESMART)
René Koning, of Rouen, FRANCE
10:00
a.m.
Washington Radiation for In-Stent
Restenosis Trial for Long Lesions (LONG WRIST)
Ron Waksman, of Washington, D.C.
10:15
a.m.
Results of the First Controlled
PK/PD Study of an Antiarrhythmic Agent in Children
J. Philip Saul, of Charleston, S.C.
10:30
a.m.
**Roxithromycin for Prevention
of Restenosis After Stenting
Franz-Josef Neumann, of Munich
TUESDAY,
MARCH 14
Late-Breaking
Clinical Trials II (#415), Arena
Co-Chairs: Desmond Fitzgerald and James T. Willerson
8:30
a.m.
The PENTALYSE Study: A New
Synthetic Pentasaccharide, as an Adjunct to Fibrinolysis
in ST-Elevation Acute Myocardial Infarction
Patrick K. Coussement, of Leuven, Belgium
8:45
a.m.
A Randomized Comparison of Low
Molecular Weight Heparin and Unfractioned Heparin Adjunctive
to t-PA Thrombolysis and Aspirin (HART II)
Allan M. Ross, of Washington, D.C.
9:00
a.m.
**Optimal Dosing of a Platelet
Glycoprotein IIb/IIIa Antagonist, Lamifiban, Using Renal-Based
Algorithms, in Patients With Acute Coronary Syndrome
(PARAGON B)
Robert A. Harrington, of Durham, N.C.
9:15
a.m.
**A Randomized Comparison of
Sibrafiban, an Oral Glycoprotein (GP) IIb/IIIa Receptor
Antagonist, With and Without Aspirin vs. Aspirin After
Acute Coronary Syndromes: Results of the Second SYMPHONY
Trial
Robert M. Califf, of Durham, N.C.
9:30
a.m.
**A Randomized Comparison of PTCA
of the Infarct Vessel and Medical Therapy in Stable
Survivors of Acute Myocardial Infarction (ALKK)
Uwe Zeymer, of Kassel, Germany
9:45
a.m.
**High-Dose Eptifibatide (Integrilin)
in Elective Coronary Stenting: Results of the ESPRIT
Trial
James E. Tcheng, of Durham, N.C.
WEDNESDAY,
MARCH 15
Late-Breaking
Clinical Trials III (#428), Arena
Co-Chairs: Jeffrey L. Anderson and James B. Young
10:45
a.m.
**Outcomes of a Prospective Trial
of Intravenous Milrinone for Exacerbations of Chronic
Heart Failure (OPTIME-CHF)
Mihai Gheorghiade, of Chicago
11:00
a.m.
**PRAISE-2: Prospective Randomized
Amlodipine Survival Evaluation
Milton Packer, of New York City
11:15
a.m.
Seven-Year Outcome in the Bypass
Angiography Revascularization Investigation (BARI)by
Treatment and Diabetic Status
Katherine M. Detre, of Pittsburgh
11:30
a.m.
**Outcomes 15 Years After Valve
Replacement With a Mechanical vs. Bioprosthetic Valve:
Final Report of the VA Randomized Trial
Shadbudin H. Rahimtoola, of Los Angeles
11:45
a.m.
Assessment of Cardioversion Using
Transesophageal Echocardiography Multicenter Study:
Clinical Outcomes at Eight Weeks (ACUTE I)
Allan L. Klein, of Cleveland
Noon
Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack (ALLHAT) Trial: Interim
Results
Barry Davis, of Houston; Curt D. Furberg, of Winston-Salem,
N.C.
|
